Zydus Lifesciences has been granted a patent for a pharmaceutical oral suspension containing mycophenolate mofetil, xanthan gum, glycerin, and other excipients in a water-based vehicle. The suspension is designed for oral delivery of various active pharmaceutical ingredients like quetiapine, sildenafil, and more. GlobalData’s report on Zydus Lifesciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Zydus Lifesciences Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Zydus Lifesciences, NSAID cancer drugs was a key innovation area identified from patents. Zydus Lifesciences's grant share as of April 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11931455B2) discloses a pharmaceutical oral suspension containing mycophenolate mofetil, xanthan gum, glycerin, and various pharmaceutically acceptable excipients. The suspension is formulated with mycophenolate mofetil at a concentration of about 200 mg/mL, xanthan gum at about 2 mg/mL, and glycerin at about 100 mg/mL, along with a vehicle comprising water. Additionally, the suspension includes one or more excipients such as an antifoaming agent, a buffer, a flavoring agent, a preservative, a sweetener, and a wetting agent to enhance its stability and palatability.

Furthermore, the patent claims an immunosuppressive method involving the administration of the pharmaceutical oral suspension to a patient in need of such treatment. By delivering a therapeutically effective amount of the suspension to the patient, the method aims to achieve immunosuppression for the management of various conditions. This innovative approach offers a convenient and potentially more effective way of administering mycophenolate mofetil, a commonly used immunosuppressive agent, to patients who require such treatment. The formulation's specific composition and method of administration outlined in the patent could have significant implications for the field of pharmaceuticals and patient care.

To know more about GlobalData’s detailed insights on Zydus Lifesciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies